Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 5/20 | 1.00 |
| ▸ | PTGER2 | P43116 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | PGR | P06401 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.47 |
| ▸ | RARB | P10826 | 1/20 | 0.47 |
| ▸ | RARG | P13631 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butaprost SCHEMBL16335459 | 1.00 | PTGIR (1.00) | PTGIRPTGER2LMNAABCC4ALDH1A1 | |
| Butaprost SCHEMBL10672693 | 1.00 | PTGIR (1.00) | PTGIRPTGER2LMNAABCC4ALDH1A1 | |
| SCHEMBL14273618 | 0.90 | PTGIR (1.00) | PTGIRPTGER2LMNAABCC4TSHR | |
| SCHEMBL13951097 | 0.90 | PTGIR (1.00) | PTGIRPTGER2LMNAABCC4TSHR | |
| SCHEMBL13143656 | 0.90 | PTGIR (1.00) | PTGIRPTGER2LMNAABCC4TSHR | |
| SCHEMBL13179799 | 0.90 | PTGIR (1.00) | PTGIRPTGER2LMNAABCC4TSHR | |
| SCHEMBL7587667 | 0.89 | PTGIR (0.84) | PTGIRPTGER2LMNAABCC4ALDH1A1 | |
| SCHEMBL14366538 | 0.89 | PTGIR (0.84) | PTGIRPTGER2LMNAABCC4ALDH1A1 | |
| SCHEMBL7586539 | 0.88 | PTGIR (0.79) | PTGIRPTGER2PGRTSHRPTGER4 | |
| SCHEMBL13179800 | 0.88 | PTGIR (0.78) | PTGIRPTGER2LMNAABCC4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339520-A1 | COMPOSITIONS AND METHODS FOR USE IN KRAS-TARGETED THERAPIES FOR THE TREATMENT OF CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-11-06 | — | — | US | claimed |
| EP-4608405-A1 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Veradermics, Incorporated (US) | 2025-09-03 | — | — | EP | claimed |
| CN-118453877-A | Application of small molecular compound combination in preparing medicine for starting liver in-situ regeneration | 中国人民解放军海军军医大学 | 2024-08-09 | — | — | CN | claimed |
| WO-2024091572-A1 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | VERADERMICS INCORPORATED (US) | 2024-05-02 | — | — | WO | claimed |
| US-20230404988-A1 | PROSTAGLANDIN RECEPTOR AGONISTS FOR USE IN THE TREATMENT OF A CORONAVIRUS INFECTION SUCH AS COVID-19 | MEDETIA (FR) | 2023-12-21 | — | — | US | claimed |
| CN-117018195-A | Application of small molecular compound or combination in preparation of medicine for starting liver in-situ regeneration | 中国人民解放军海军军医大学 | 2023-11-10 | — | — | CN | claimed |
| EP-4225319-A1 | PROSTAGLANDIN RECEPTOR AGONISTS FOR USE IN THE TREATMENT OF A CORONAVIRUS INFECTION SUCH AS COVID-19 | Medetia (FR) | 2023-08-16 | — | — | EP | claimed |
| CN-112661836-B | Purification method of buminuo peptide | 江苏诺泰澳赛诺生物制药股份有限公司 | 2023-04-07 | — | — | CN | claimed |
| US-20220401487-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | FATE THERAPEUTICS, INC. | 2022-12-22 | — | — | US | claimed |
| US-11413309-B2 | Compositions and methods for immune cell modulation in adoptive immunotherapies | FATE THERAPEUTICS, INC. (US) | 2022-08-16 | — | — | US | claimed |
| EP-1385550-A2 | THERAPEUTIC METHOD FOR INDUCING TOLERANCE | Medical Research Council (GB) | 2004-02-04 | — | — | EP | claimed |
| WO-2003094957-A2 | METHODS OF THERAPY FOR INDUCING TOLERANCE | MEDICAL RESEARCH COUNCIL (GB) | 2003-11-20 | — | — | WO | claimed |
| WO-2003090699-A1 | COSMETIC COMPOSITION FOR PROMOTING HAIR GROWTH AND/OR PREVENTING OR DELAYING HAIR LOSS | L'OREAL (FR) | 2003-11-06 | — | — | WO | claimed |
| EP-1358868-A2 | Cosmetic composition for increasing hair growth and/or for preventing or delaying hair loss | L'OREAL (FR) | 2003-11-05 | — | — | EP | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| WO-2002092097-A1 | COMPOSITION COMPRISING PHOSPHODIESTERASE INHIBITORS FOR INDUCING CERVICAL RIPENING | MEDICAL RESEARCH COUNCIL (GB) | 2002-11-21 | — | — | WO | claimed |
| WO-2002092064-A2 | THERAPEUTIC METHOD FOR INDUCING TOLERANCE | MEDICAL RESEARCH COUNCIL (GB) | 2002-11-21 | — | — | WO | claimed |
| WO-1996008254-A1 | USE OF BUTAPROST IN PRE-TERM LABOUR | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1996-03-21 | — | — | WO | claimed |
| US-4742080-A | Therapeutic method for producing bronchodilation by administration of 15-deoxy-16-hydroxy prostaglandin esters | MILES LABORATORIES, INC. (US) | 1988-05-03 | — | — | US | claimed |
| US-4275224-A | BRONCHODIALATORS AND ANTI-GASTRIC SECRETION AGENTS | MILES LABORATORIES, INC. (US) | 1981-06-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230404988-A1 | PROSTAGLANDIN RECEPTOR AGONISTS FOR USE IN THE TREATMENT OF A CORONAVIRUS INFECTION SUCH AS COVID-19 | PTGER4, PTGER2, PTGER1 | PTGIR 4/4885PTGER2 2/4885LMNA 3524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.